DelMar Pharmaceuticals adds three oncologists to Scientific Advisory Board
21 May 2019 -

DelMar Pharmaceuticals Inc (Nasdaq: DMPI), a biopharmaceutical company focused on the development and commercialisation of new cancer therapies, announced yesterday that it has named three oncologists to its Scientific Advisory Board.

The company has added Dr David Reardon, clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and a professor of medicine at the Harvard Medical School to its Scientific Advisory Board; Dr Timothy Cloughesy, professor of neurology at the David Geffen School of Medicine at the University of California, Los Angeles and a member of the UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center; Dr Nicholas Butowski, a neuro-oncologist practicing at UCSF Medical Center in San Francisco, California, and director of translational research in neuro-oncology and a researcher at the Brain Tumor Center.

These new advisors join the present Scientific Advisory Board members Dr John de Groot, chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Centre and Dr Napoleone Ferrara, scientist and distinguished professor of pathology and a distinguished adjunct professor of ophthalmology and pharmacology at the University of California, San Diego. Dr Ferrara will serve as chairman of the company's Scientific Advisory Board.